Fallopian tube carcinoma (FTC) is a rare, poorly studied and aggressive cancer, associated with poor survival. Since tumorigenesis is related to the acquisition of genetic changes, we used genome-wide array comparative genomic hybridization to analyse copy number aberrations occurring in FTC in order to obtain a better understanding of FTC carcinogenesis and to identify prognostic events and targets for therapy. We used arrays of 2464 genomic clones, providing B1.4 Mb resolution across the genome to map genomic DNA copy number aberrations quantitatively from 14 FTC onto the human genome sequence. All tumors showed a high frequency of copy number aberrations with recurrent gains on 3q, 6p, 7q, 8q, 12p, 17q, 19 and 20q, and losses involving chromosomes 4, 5q, 8p, 16q, 17p, 18q and X. Recurrent regions of amplification included 1p34, 8p11-q11, 8q24, 12p, 17p13, 17q12-q21, 19p13, 19q12-q13 and 19q13 . Candidate, known oncogenes mapping to these amplicons included CMYC (8q24), CCNE1 (19q12-q21) and AKT2 (19q13), whereas PIK3CA and KRAS, previously suggested to be candidate driver genes for amplification, mapped outside copy number maxima on 3q and 12p, respectively. The FTC were remarkably homogeneous, with some recurrent aberrations occurring in more than 70% of samples, which suggests a stereotyped pattern of tumor evolution. Oncogene (2003 Oncogene ( ) 22, 4281-4286. doi:10.1038 Keywords: array CGH; CCNE1; AKT2; fallopian tube cancer Fallopian tube carcinoma (FTC) is an aggressive form of cancer in women that is associated with a poor survival. Previous studies have reported that FTC show an aneuploid DNA content, overexpression of TP53, ERBB2 and CMYC (Hellstro¨m et al., 1994; Chung et al., 2000) , as well as a high frequency of KRAS mutations (Mizuuchi et al., 1995) . Deficiency for BRCA1 may also contribute to the genesis of FTC, since the incidence of FTC is higher in families carrying BRCA1 mutations (Zweemer et al., 2000; Aziz et al., 2001; Leeper et al., 2002) and dysplasia is a frequent finding in prophylactically removed Fallopian tubes from BRCA1 carriers (Piek et al., 2001) . However, the application of chromosome comparative genomic hybridization (CGH) to the study of FTC revealed that these tumors are characterized by a high level of copy number aberrations with frequent amplification of 3q (Heselmeyer et al., 1998; Pere et al., 1998) . Thus, there appear to be many genes, in addition to the commonly studied oncogenes and tumor suppressors that contribute to the genesis of FTC. Detecting and quantifying these copy number changes may lead to a better understanding of FTC carcinogenesis and might identify prognostic events and targets for the choice or design of therapy.
Here, we report on the application of array CGH to further refine regions of recurrent aberration in FTC. Array CGH provides a means to detect genomic DNA copy number aberrations quantitatively and map them directly onto the sequence of the human genome (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Pollack et al., 1999; Snijders et al., 2001) . We used an array comprised of 2464 genomic clones, each mapped to the August 2001 freeze of the human genome sequence, to determine the copy number profiles of 14 FTC. The tumors ranged in FIGO stage from Ia to IV and included one grade 1, seven grade 2 and six grade 3 tumors. Patient age at diagnosis ranged from 46 to 82 years, and one patient met the criteria for family cancer syndrome. Copy number profiles for three tumors are shown in Figure 1 and illustrate the high frequency of copy number alterations in these tumors in agreement with the limited chromosome CGH data reported previously (Heselmeyer et al., 1998; Pere et al., 1998) . Using previously described statistical methods (Snijders et al., 2003) , we determined the frequency of the different types of copy number aberrations distinguished by array CGH, including low-level copy number alterations affecting whole chromosomes or portions of chromosomes, and more focal aberrations such as deletions and high-level copy number increases, or amplifications. We observed an average of 94 aberrations per tumor (range 37-146). Copy number alterations involving whole chromosome gains and losses were rare. On the other hand, copy number alterations affecting chromosome arms or portions of arms, which we scored as transitions from one copy number to another along a chromosome were frequent (average 55 per tumor, range 22-85 per tumor). There were no significant correlations of copy number aberrations with stage or grade.
We observed recurrent regions of aberration as shown by the frequency plot of gains or losses recorded on each clone ( Figure 2a ). Many of these regions were found previously by chromosome CGH, including recurrent copy number gains on 3q, 6p, 7q, 8q, 12p, 17q and 20q, and losses involving chromosomes 4, 5q, 8p, 16q, 17p and 18q. However, the application of array CGH mapped these regions with higher resolution and also found regions of chromosome 19 and X that were consistently gained or amplified (14/14 tumors) and lost (13/14 tumors), respectively. Regions of amplification were also observed, a number of which had previously not been reported (Table 1) . Several of these regions would have been difficult to detect by chromosome CGH as they map near the centromeres or telomeres of the chromosomes. These regions, in addition to chromosome 19, often display copy number artefacts by chromosome CGH (Kallioniemi et al., 1994; Karhu et al., 1997) , which are not encountered in array CGH .
Gain or amplification of the distal part of chromosome 3q, centering on 3q26, has been reported in many tumors. Here, we resolved two regions of gain on distal 3q, including one centered on 3q25-26 (7/14 tumors) and one centered on 3q26-27 (10/14 tumors). Candidate genes that map to the 3q25-26 region, which is flanked by RP11-198G24 and RP11-172G5, include TERC, which has been suggested as a driver gene for this amplification (Heselmeyer et al., 1998) , as well as TNFSF10, EVI1 and SKIL, which are also good candidates. The more distal region of gain at 3q26-27 is flanked by RP11-118F4 and CTD-2091K6. Candidate genes in this region include THPO and MAP3K13. The oncogene, PIK3CA, which has been reported to be at increased copy number in many ovarian tumors maps in c Figure 1 Genome-wide DNA copy number analysis of three Fallopian tube carcinoma. Array CGH was carried out using arrays of 2464 BAC clones each printed in triplicate (HumArray2.0) according to published protocols (Snijders et al., , 2003 . The majority of the BACs used for the array were obtained from FISH verified clone sets (Knight et al., 2000; Cheung et al., 2001) . The array has been extensively validated for its capability to reliably detect and map changes from single copy in a diploid background, as well as high level amplifications . Tumor DNAs were extracted from 20 microdissected consecutive 10 mm formaldehydefixed paraffin-embedded sections ) using a QIAmp DNA minikit following a modification of the manufacturer's protocol (Weiss et al., 1999) . The tumor genomic DNA and normal female reference DNA (300 ng each) were labeled by random priming in separate 50 ml reactions to incorporate Cy3 and Cy5, respectively. The test and reference DNAs together with 100 mg human Cot-1 DNA were hybridized to the BAC arrays for B48 h at 371C. After posthybridization washes, the arrays were mounted in a solution containing 90% glycerol, 10% PBS and 1 mm DAPI and sealed with a coverslip. A custom-built CCD camera system was used to acquire 16 bit 1024 Â 1024 pixel DAPI, Cy3 and Cy5 images (Pinkel et al., 1998) . Image analysis was carried out using UCSF SPOT software (Jain et al., 2002) . The log 2 ratio of the total integrated Cy3 and Cy5 intensities for each spot after background subtraction was calculated, normalized to the median log 2 ratio of all the clones on the array and the average of the triplicates calculated using a second custom program, SPROC. Automatic data filtering to reject data points based on low DAPI intensity, low correlation between Cy3 and Cy5 within each segmented spot and low reference/DAPI signal intensity was also carried out using SPROC. Data files were subsequently manually edited by rejecting clones for which only one spot of the triplicate survived after SPROC analysis and for which the standard deviation of the log 2 ratio of the triplicate was 40.2. For each tumor, the data are plotted as the mean log 2 ratio of the triplicate spots for each clone normalized to the genome median log 2 ratio. 
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Array CGH analysis of Fallopian tube cancers AM Snijders et al between these two regions of frequent copy number gain/amplification on distal 3q. If driver genes for amplification map to the copy number maximum in regions of amplification (Albertson et al., 2000) , then these observations suggest that PIK3CA is not the driver gene for either recurrent aberration. However, increased copy number of PIK3CA was observed in six FTC and thus increased copy number of PIK3CA may still contribute to the genesis of FTC. Loss of 8p has frequently been observed in many solid tumors. Here, we found 8p loss in all FTC tumor samples. The minimal region of recurrent loss was located at 8p23 in 12/14 tumors and is flanked by RP11-82K8 and RP11-140K14. The cub and sushi multiple domains-1 gene CSMD1 is currently the only named gene in this region (UCSC June 2002 freeze). Although the region is frequently deleted in a number of different tumor types, little is known about the function of this gene (Sun et al., 2001) . We also found a previously unreported region of gain (5/14 tumors) or amplification (2/14 tumors) mapping at proximal 8p. The region is flanked by RP11-48D21 and RP11-73M19 and does not include FGFR1 (Figure 2c ). Several candidate oncogenes mapping to this region include PLAT, POLB and ANK1.
A high frequency of KRAS mutations has been previously reported in FTC (Mizuuchi et al., 1995) . Although we find chromosome 12p to be gained or amplified in at least six FTC, KRAS, which is included in 2/6 copy number gains, maps outside of the minimal recurrent region of copy number gain, which is flanked by GS1-124K20 and RP11-24N12. Candidate Three regions of chromosome 19 were gained or amplified with one or more regions being affected in all 14 tumors. Aberrations at 19p13-p12 were observed in 12/14 tumors. This minimal region is flanked by RP11-84C17 and RP11-107O2 (Figure 2d ). Several cancerrelated genes map to this region, including JUNB, RAD23A, BRG1, RAB3D and RAB11B. The second region of frequent copy number increase is located at chromosome 19q13 (Figure 2d ). This region is gained in 9/14 FTC and amplified in 2/14 FTC. The minimal region of amplification is flanked by RP11-92J4 and RP11-208I3 and includes the oncogene AKT2, coding for a serine-threonine protein kinase involved in increased survival and proliferation. Previous studies have shown that AKT2 is amplified/overexpressed (Cheng et al., 1992; Bellacosa et al., 1995) or activated in ovarian cancers (Yuan et al., 2000) . However, AKT2 is not included in 3/9 copy number gains suggesting that other genes in this region contribute to FTC carcinogenesis. Amplification of the third region on chromosome 19 at 19q12-13, flanked by RP11-152P7 and RP11-147D7 was observed in four FTC. The region was also gained in an additional six FTC. The copy number maximum of this amplicon encompasses CCNE1. Previous studies have found CCNE1 amplifications in ovarian, colon, gastric, esophageal and urinary bladder cancer (Akama et al., 1995; Kitahara et al., 1995; Marone et al., 1998; Lin et al., 2000; Richter et al., 2000) . Upregulation of CCNE1 may contribute to tumorigenesis by accelerating progression through G1/ S, although other oncogenic functions have been described, in addition to its ability to promote cell cycle progression (Geisen and Mo¨ro¨y, 2002) , including, for example, malignant transformation in cooperation with HRAS and CMYC (Haas et al., 1997) and genomic instability (Spruck et al., 1999) .
Losses of the X chromosome or parts thereof were observed in 13/14 FTC and will result in different functional consequences depending on whether the active or inactive X is lost. If the active X is lost, the cells will be effectively homozygous null for genes subject to X inactivation, while loss of the inactive X should result in altered expression of fewer genes (those that escape X inactivation). A tendency toward loss of the late replicating X has been reported previously in solid tumors in females (Dutrillaux et al., 1986) and thus, its loss may provide a proliferative advantage.
The observed high frequency of recurrence of aberrations, some occurring in 70% or more of the cases indicated that the Fallopian tube cancers were remarkably homogeneous in their copy number profiles (Figure 3) . A comparison of the copy number aberrations across the set of 14 tumors revealed that the data set was highly correlated (average Spearman's rank correlations of the pairs of tumors is 0.47). We have previously reported that specific defects in pathways that normally maintain genomic stability give rise to certain types and frequencies of copy number aberrations (Snijders et al., 2003) . The data reported here suggest a limited number of routes lead to FTC pathogenesis.
It has been noted previously that serous carcinoma of the Fallopian tubes, uterus and ovary are similar histologically and in their clinical behavior, including invasion and poor prognosis (Pere et al., 1998) . They also share a number of genetic features including a high frequency of TP53 overexpression (Hellstro¨m et al., 1994; Caduff et al., 1998) , amplification and overexpression of certain oncogenes including ERBB2 and CMYC in all three types (Monk et al., 1994; Wang et al., 1999; Chung et al., 2000; Manavi et al., 1998) and AKT2 in ovarian (Yuan et al., 2000) and Fallopian tube cancers as shown here. They also have similar chromosome CGH profiles (Pere et al., 1998) . These similarities may reflect the fact that the Fallopian tubes, ovarian surface epithelium and uterus develop from the Mu¨llerian ducts and thus cells from this lineage may tiptoe towards cancer via similar pathways. Further insights await higher resolution analysis of the genomewide aberrations in these other tumor types by array CGH.
